BiomX (NYSEAMERICAN:PHGE) Trading 10.5% Higher – Still a Buy?

BiomX Inc. (NYSEAMERICAN:PHGE) shares shot up 10.5% during trading on Friday . The company traded as high as $0.9861 and last traded at $0.8165. 12,371,591 shares changed hands during mid-day trading, a decline of 3% from the average session volume of 12,752,066 shares. The stock had previously closed at $0.7389.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, BiomX currently has a consensus rating of “Hold” and a consensus price target of $26.00.

BiomX Trading Up 10.5%

The firm has a market capitalization of $1.30 million, a price-to-earnings ratio of -0.25 and a beta of 1.02. The stock’s fifty day moving average price is $2.50 and its two-hundred day moving average price is $3.79.

BiomX (NYSEAMERICAN:PHGE) last issued its earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. Analysts anticipate that BiomX Inc. will post -5.85 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Reuven Yeganeh sold 530,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 21.80% of the company’s stock.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. Institutional investors own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.